MedTrace Logo

Clinical Investigation to Assess the Effect of Betaglucan Administration in HPV Patients

NCT06987396 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2025-05-23

No results posted yet for this study

Summary

Randomised, controlled clinical study to assess the efficacy and tolerability of an oral supplementation of 1000 mg daily of Betaglucans in the evolution of patients with Human Papilloma Virus (HPV). The improvement is measured by DNA PCR test, cytology and a specific RNA test.

Conditions

Interventions

DIETARY_SUPPLEMENT

1000 mg Betaglucans (daily)

Patients in the experimental group receive betaglucans supplement in capsule form, administered orally

Sponsors & Collaborators

  • Vitae Health Innovation

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-15
Primary Completion
2025-05-15
Completion
2025-05-15

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06987396 on ClinicalTrials.gov